

82. A method for identifying a compound which modulates the activity of a polypeptide of claim 67, comprising:

- a) contacting a polypeptide of claim 67 with a test compound; and
- b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

83. A method for identifying an agent that modulates the level of expression of a nucleic acid molecule of claim 60 in a cell, said method comprising contacting said agent with the cell expressing said nucleic acid molecule such that said level of expression of said nucleic acid molecule can be modulated in said cell by said agent and measuring said level of expression of said nucleic acid molecule.

at
cont
84. A method for modulating the level of expression of a nucleic acid molecule of claim 60, said method comprising contacting said nucleic acid molecule with an agent under conditions that allow the agent to modulate the level of expression of the nucleic acid molecule.

85. A pharmaceutical composition containing any of the polypeptides in claim 67 in a pharmaceutically acceptable carrier.--

REMARKS

The foregoing amendments to the claims are fully supported in the specification as originally filed. Accordingly, the foregoing amendments to the claims do not add new matter; their entry is therefore respectfully requested.


In re: Glucksmann *et al.*
Appl. No.: 09/464,685
Filed: December 16, 1999
Page 8

Applicants believe that the present application is now in condition for examination. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of the foregoing amendments, and entry of the same into the present application, are respectfully requested.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,




Leslie T. Henry
Registration No. 45,714

ALSTON & BIRD LLP
P.O. Drawer 34009
Charlotte, NC 28234
Tel Raleigh Office (919) 420-2200
Fax Raleigh Office (919) 420-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box Missing Parts, Assistant Commissioner For Patents, Washington, DC 20231, on April 10, 2000.



Nora C. Martinez